Drug Trial Radar · NCT06508021
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Oct 25, 2024
Primary completion
Feb 4, 2029
Study completion Feb 4, 2029
Sponsor
- Lead sponsor
- Ashibio IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking at several research questions, including: * Safety of andecaliximab in participants with FOP * Whether andecaliximab reduces the number of new heterotopic bone lesions (Heterotopic Ossification; HO) * Whether andecaliximab reduces the number or severity of flare-ups * Pharmacokinetics/pharmacodynamics (PK/PD): How much study drug is in your blood at different times and its impact on blood biomarker(s) * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
AndecaliximabDrug
Dose level A or B
PlaceboDrug
Blinded
AndecaliximabDrug
Dose level A or B (or age adjusted dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]Time frame: Week 27 and 53
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco (UCSF)
San Francisco, California
Mayo Clinic
Rochester, Minnesota
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.